Genomic Medicine Laboratory, Culiacan General Hospital, Sinaloa, Mexico.
Faculty of Chemical and Biological Sciences, Autonomous University of Sinaloa, Mexico
Iran J Immunol. 2022 Sep;19(3):311-320. doi: 10.22034/iji.2022.92641.2162.
Coronavirus disease 2019 (COVID-19) is an emergent viral disease in which the host inflammatory response modulates the clinical outcome. Severe outcomes are associated with an exacerbation of inflammation in which chemokines play an important role as the attractants of immune cells to the tissues.
To evaluate the relationship of the chemokines IL-8, RANTES, MIG, MCP-1, and IP-10 with COVID-19 severity and outcomes in Mexican patients.
We analyzed the serum levels of IL-8, RANTES, MIG, MCP-1 and IP-10 in 148 COVID-19 hospitalized patients classified as mild (n=20), severe (n=61), and critical (n=67), as well as in healthy individuals (n=10), by flow cytometry bead array assay.
Chemokine levels were higher in patients than in the healthy individuals, but only MIG, MCP-1, and IP-10 increased according to the disease severity, showing the highest levels in the critical group. MIG, MCP-1, and IP-10 levels were also higher in COVID-19 patients with comorbidities such as renal disease, type 2 diabetes, and hypertension. Moreover, elevated MIG levels seem to be related to organic failure/shock, and an increased risk of death.
Our results suggest that the increased levels of MCP-1, IP-10, and especially MIG might be useful in predicting severe COVID-19 outcomes and could be promising therapeutic targets.
2019 年冠状病毒病（COVID-19）是一种新出现的病毒性疾病，宿主炎症反应调节着临床结果。严重的结果与炎症的加剧有关，趋化因子在吸引免疫细胞到组织中起着重要作用。
评估趋化因子 IL-8、RANTES、MIG、MCP-1 和 IP-10 与墨西哥 COVID-19 患者严重程度和结局的关系。
我们通过流式细胞术珠阵列分析，分析了 148 例住院 COVID-19 患者（轻度 n=20，严重 n=61，危重症 n=67）和 10 名健康个体的血清中 IL-8、RANTES、MIG、MCP-1 和 IP-10 水平。
与健康个体相比，患者的趋化因子水平更高，但只有 MIG、MCP-1 和 IP-10 根据疾病严重程度增加，在危重症组中水平最高。患有肾脏疾病、2 型糖尿病和高血压等合并症的 COVID-19 患者的 MIG、MCP-1 和 IP-10 水平也更高。此外，升高的 MIG 水平似乎与器官衰竭/休克有关，并且死亡风险增加。
我们的结果表明，MCP-1、IP-10 和特别是 MIG 的水平升高可能有助于预测严重 COVID-19 的结局，并且可能是有前途的治疗靶点。
